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Background: The Fracture Risk Assessment (FRAX) tool has been developed by the World Health Organization
(WHO) to calculate 10-year probability hip fracture (HP) or major osteoporotic fracture (MOF). The objective of this
study was to assess the 10-year probability of MOF and HF among a selected sample of Palestinian people.
Methods: A sample of 100 subjects was studied. Dual energy X-ray absorpitometry was performed to measure
bone mineral density (BMD) which was then inserted into FRAX Palestine online WHO tool to calculate the 10-year
probability of MOF and HF.
Results: The median age of participants was 61.5 years and the majority (79%) were females. The median
(interquartile range) of femoral hip BMD was 0.82 (0.76-0.92) g/cm2. The mean vertebral and hip T scores
were −1.41 ± 0.13 SDs and −0.91 ± 0.10 SDs respectively. About one fifth of the sample (21%) had vertebral
osteoporosis and 5% had hip osteoporosis. The median (interquartile range) 10-year probability of MOF and HF
based on BMD were 3.7 (2.43-6.18)%, and 0.30 (0.10-0.68)% respectively.
Conclusion: Osteoporosis is common among Palestinian people above 50 years old. Bone fracture prevention
strategies and research should be a priority in Palestine. Using FRAX might be a helpful screening tool in primary
healthcare centres in Palestine.
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Osteoporosis is a progressive silent disease affecting bone
mass and structure, leading to increased susceptibility to
fractures [1,2]. The most common sites for osteoporotic
fractures are the spine, hip, and wrist. Hip fractures (HP)
are particularly devastating [3-5]. The World Health
Organization (WHO) recently designed a tool to estimate
the 10-year probability of HF and major osteoporotic frac-
ture (MOF). This tool is called Fracture Risk Assessment
Tool (FRAX) [6]. The tool, FRAX, is based on 11 risk fac-
tors plus the hip bone mineral density (BMD) if available.
Each of the 11 factors used in FRAX tool provides some
degree of independent information about fracture risk.
These factors include age, sex, weight, height, a prior* Correspondence: waleedsweileh@yahoo.com
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reproduction in any medium, provided the orfragility fracture, parental history of HF, current tobacco
smoking, long-term use of glucocorticoids, rheumatoid
arthritis, other causes of secondary osteoporosis and daily
alcohol consumption. Since osteoporosis is a multi-
factorial disease, combination of risk factors with BMD
produces the most effective risk assessment for MOF as
opposed to assessment of any risk factor alone [7].
FRAX is intended for use in postmenopausal women and
men over the age of 40 who have not taken osteoporosis
medications. The tool is available online at (http://www.
shef.ac.uk/FRAX/tool.aspx?country=52). Normal BMD or
bone mineral content (BMC) is defined by the WHO as
BMD or BMC score between ± 1 standard deviations (SDs)
from the young adult mean, as measured by central (hip
or spine) dual energy x-ray absorpitometry (DEXA) scan
[8]. Osteopenia is clinically defined as a BMD score
between −1 and −2.5 SDs and osteoporosis as a BMD
score 2.5 SDs or more below the young adult mean. Thed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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veloped guidelines based on FRAX and currently rec-
ommends starting treatment in individuals with any one
of the following criteria: (1) history of hip or vertebral
fracture, (2) T-score ≤ −2.5 at femoral neck or spine, (3)
T-score between −1.0 and −2.5 and 10-year probability ≥
3% for hip fractures and ≥ 20% for MOF [9].
Palestine, or called the occupied Palestinian territories
is located in the Middle East area. According to the lat-
est report published by the Palestinian ministry of health
(http://www.moh.ps/attach/441.pdf), Palestine has a total
population of (4,168,858); (50.8%) are males and (49.2%)
are females. Population pyramid shows that (40.8%) of the
Palestinian population is under 15 years old, 14.7% is in
the age group (0–4) years, and 2.9% is above 65 years. The
natural increase of population was 2.9%, and the crude
birth rate was (29.1/1,000) while fertility rate was 4.3. The
five main health providers of health services in Palestine
are Ministry of health (MOH), the United Nations Relief
and Works Agency for Palestine Refugees in the Near East
(UNRWA), Palestinian Non-Governmental Organizations
(NGOs), Palestinian Military Medical Services (PMMS)
and Private for profit organizations. The Palestinian MOH
bears the heaviest burden, as it has the major responsibil-
ity. The NGOs sector operates more than 200 primary
health care centres and general clinics in Gaza Strip and
West Bank [10].
To the best of authors’ knowledge, no studies have
been carried out in Palestine or in other neighbouring
Arab countries using FRAX® to estimate the 10-year
probability bone fracture. Therefore, this study was
carried out to measure the BMD and calculate the
10-year probability hip and MOF in a selected sample
of Palestinian men and women older than 50 years.Methods
Study design and setting
This study was a descriptive analytical study carried out
at Al-Rahmah center which is a nongovernmental charit-
able organization that provides medical services for the
general public. It includes outpatient specialist clinics,
pharmacy, radiology and laboratory departments. It has
a relatively high workload and it is the only center that
provides DEXA in Nablus district, Palestine.Sampling method and ethical consideration
Data collection process took place during April – June,
2012. One of the investigators visited Al-Rahmah center
daily and stayed there from 9 am to 1 pm to recruit partic-
ipants. Potential candidates were approached and were in-
vited to participate. Males or females above 50 years who
did not have osteoporosis and were not using osteoporotic
medication, except for calcium and vitamin D, wereincluded in the study. Those having recent osteoporotic
fractures were excluded.
Ethical approval was obtained from Institutional Review
Board (IRB) at An-Najah National University. In addition,
approval from Al-Rahmah clinic administration, and con-
sent forms from participants were also obtained. Partici-
pants were assured privacy and confidentiality of data.Data collection tool
The questionnaire used consisted of 1) socio-demographic
information including sex, age, educational level, and mari-
tal status, 2) anthropometric measures including height,
weight, and BMD, 3) medication and medical history of
the participants and 4) dichotomous risk factors of FRAX
tool.
Bone mass density was obtained by performing DEXA
using Hologic DEXA machine at Al-Rahmah clinic radi-
ology department. The hologic DEXA machine was set
for white Mediterranean as reference value. Further clas-
sification was made based on the WHO classification for
osteoporosis (BMD value is - 2.5 SD or more below the
mean for young adult mean) and osteopenia (BMD value
between −2.5 SD and −1 SD) to classify the subjects
according to vertebral and hip osteoporosis. Weight and
height were also recorded. Height was measured also by
tape measure. When using FRAX/ Palestine tool, the
DEXA result was entered as BMD measurement. The on-
line FRAX tool calculates the 10-year probability of both
HF and MOF.Data analysis
The independent variables included in this study were:
age (above 50 years); sex; marital status (single, married,
widowed, and divorced); parity and use of oral contracep-
tives (OCT) in females; weight (kg) and height (meter) to
calculate body mass index (BMI); level of education
(illiterate, basic education (1st to 10th grade), high school
education, and college); administered medications, and
chronic illnesses. Other investigated variables such as
history of previous fracture, history of parental fracture,
alcohol consumption, tobacco smoking, history of glu-
cocorticoids use, rheumatoid arthritis, other secondary
causes of osteoporosis, and exercise were presented as
dichotomous variable. Secondary osteoporosis is present
if the patient has a disorder strongly associated with
osteoporosis. These include type I (insulin dependent)
diabetes, osteogenesis imperfecta in adults, untreated
long-standing hyperthyroidism, hypogonadism or pre-
mature menopause (<45 years), chronic malnutrition,
mal-absorption or chronic liver disease. The outcome
variable in this study was the 10-year probability HF
and MOF calculated by the WHO FRAX tool for
Palestine.
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Package for Social Sciences (SPSS) version 16.0 for Win-
dows. Normality was tested using Kolmgorov-Smirnov
test. Descriptive analysis for continuous variables was
performed with mean and SDs or median and (inter-
quartile range). Frequencies and percentages were calcu-
lated for categorical variables. Correlation was used to
test relationship between BMD and 10-year probability
of HF or MOF. Mann–Whitney U test was used to test
association between groups for variables that were not
normally distributed. Differences were considered sig-
nificant if the P-value was less than 0.05.
Results
Demographic and clinical characteristics of the
participants
One hundred and twenty people were invited to partici-
pate in the study, 12 refused to participate while 8 did
the interview but refused to do the DEXA test, giving a
net total sample of 100 subjects (Figure 1). Demo-
graphic and clinical characteristics of the participants
are shown in Table 1. Age showed positive skewness
with a median age (interquartile range) of 61.5 (55–67)120 subjects were invited to participate 
during the study period of June – July/ 2012 
100 subjects met the inclusion 
criteria and did the DEXA test.
8 subjects refused to do the DEXA 
test 
108 subjects agreed to participate 
and met the inclusion criteria
Figure 1 Number and response of subjects who were invited
to participate.years. The majority (79%) of participants were females.
The mean ± SD of BMI of the study sample was 32.20 ±
4.69; for males was 28.92 ± 4.91, and for females was
33.07 ± 4.26. Nineteen percent of the participants were
current tobacco users and 38% exercised routinely at
least 30 minutes a day three times a week. More than
half of female participants (53.16%) reported using oral
contraceptives in the past. Twenty two percent of the
participants had used oral corticosteroids. Twenty-two
percent suffered from previous fracture and 15% had at
least one parent with previous HF.
Dual energy X-ray
The results of BMD had a median (interquartile range) of
0.82 (0.76 - 0.92). The mean vertebral T score was −1.41 ±
0.13 SDs and the mean hip T score was - 0.91 ± 0.095 SDs.
Based on the WHO criteria, 21% of the participants had
vertebral osteoporosis, 29% had vertebral osteopenia
and 50% were normal. Based on hip T scores, 5% had
hip osteoporosis, 23% had hip osteopenia, and 72% were
normal. Taken altogether, 23% had osteoporosis whether
hip or vertebral (Table 2).
Fracture risk assessment tool
Using FRAX calculator with BMD data, the median 10-
year (interquartile range) probability for MOF was 3.7%
(2.43 – 6.18) and that for HF was 0.3% (0.10 - 0.68).
Two participants were at high risk of MOF (≥20%) and
4 were at high risk of HF (≥3%). Based on the NOF
guideline, at least 24 participants needed immediate treat-
ment. Table 3 shows data extracted from FRAX calculator.
BMD was significantly and negatively correlated with both
10-year probability of MOF (p <0.001, r = − 0.609) and
HF (p <0.001, r = − 0.845).
The median 10-year probability of MOF calculated
based on BMD was significantly (p <0.05) associated with
age > 65 years, female gender, patients who have more
than 6 children, low educational level, history of previous
fracture, history of parents’ HF, history of no OCT use
among females, history of oral corticosteroid use, second-
ary osteoporosis, and presence of rheumatoid arthritis but
not with marital status, smoking, BMI, performing exer-
cise, diabetes mellitus, and presence of cardiovasular dis-
eases (CVD) or gastrointestinal tract (GIT) diseases.
The median 10–year probability of HF calculated
based on BMD was significantly (p <0.05) associated
with age > 65 years, patients who have high number of
children (more than 6 children), low educational level,
previous HF, secondary osteoporosis, use of corticoste-
roids, secondary osteoporosis, presence of GIT diseases
and rheumatoid arthritis but not with gender, marital
status, current tobacco smoking, BMI, exercising, previ-
ous history of parents’ hip fractures, history of OTC use,
and history of CVD.
Table 1 Demographic and clinical characteristics of the
participants
Variable name Statistics Mean ± SD or Median
(interquartile range) or N (%)
Age (years) 61.5 (55–67 )
50 < Age ≤ 65 72 (72%)






Others (single, widowed, or divorced) 9 (9%)
Parity (for females)
Nulliparity 8 (10.13%)
Have≤ 6 children 29 (37.05%)
Have > 6 children 42 (53.16%)
Education
Illiterate 18 (18%)
School educated 58 (58%)




Body mass index 32.20 ± 4.69 g\cm2
For males 28.92 ± 4.91 g\cm2







Previous parents’ hip fracture
Yes 15 (15%)
No 85 (85%)
History of OCT use among females
Yes 37 (53.16%)
No 42 (46.84%)




















Abbreviations: SD standard difference, OCT oral contraceptives.
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The problem of osteoporosis will soon be of greater im-
portance in developing countries due to the increase in
life expectancy [11]. In the Middle East, the burden of
this disease is expected to increase taking into account
the steady growth of the ageing population. A study in
Iran indicated that 2 million people are at risk of frac-
ture and the cost of HF is between 6 – 8 million United
Sates dollars (USD) [12]. The prevalence of osteoporosis
in post-menopausal Iranian women was reported to be 6
percent which is remarkably low compared to other
countries. A recent survey conducted in Lebanon to de-
termine risk factors for osteoporosis in the Lebanese fe-
male population found that back pain, low physical
activity, family history of osteoporosis or HF, loss of
height, early menopause, heavy smoking (>20 cigarettes
per day), thin and small build, history of rheumatoid or
thyroid disease, previous administration of corticoste-
roids and chronic alcohol consumption were associated
with increased MOF [13]. In Saudi Arabia, the preva-
lence of osteoporosis was studied in a group of randomly
selected males and females aged 20–79 years; the preva-
lence in women was 28.2% [14]. In a study carried out in
Qatar on healthy females aged 20 to 70, risk factors for
osteoporosis were similar to those known to influence
BMD in other populations; female sex, age, early meno-
pause, and smoking [15]. In Palestine, a study conducted
by Abd-Alhameed et al. (2010) on the prevalence and
awareness to osteoporosis among randomly selected post-
menopausal women found that osteoporosis at lumbar
spine, neck and total hip was 24%, 14% and 29.7% respect-
ively [16]. The authors of the Palestinian study concluded
that BMD values declined 0.32-0.53% per year in relation
to the number of years after menopause.
Several studies in Europe and Asia were carried out to
assess the 10-year risk probability for bone fracture using
Table 2 Results obtained from Dual Energy X-rays (DEXA)
Variable name Statistics Mean ± SD or Median
(interquartile range), N (%)
Bone mineral density (hip) 0.82 (0.76 - 0.92) g\cm2
Vertebral T score −1.41 ± 0.13








Hip osteopenia 23 (23%)
Hip osteoporosis 5 (5%)
Abbreviations: SD standard difference.
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in Bulgaria among women > 50 years found that the mean
10-year absolute fracture risk was 13.4 ± 9.2% (major frac-
tures) and 2.8 ± 5.2% (HP) [17]. A study in Taiwan found
that the mean 10-year probabilities of MOF or HF were
13.8% (95% confidence interval (CI) = 10.7%-16.9%) and
2.2% (95% CI = 0.8%-3.5%), respectively [18]. A study in
Poland among 2012 post-menopausal women found that
the mean 10-year probability of MOF or HF was 22.2 ±
12.1% [19]. It is evident that the values obtained in our
study were lower than that reported in other international
studies. This difference could be attributed to geograph-
ical, cultural and nutritional habits in different parts of the
world.
Osteoporosis is a major public health problem because
of the fractures that could occur. Unfortunately, osteo-
porosis receives low attention in the primary health care
programs in most underdeveloped countries where most
women are largely unaware of the serious complications
associated with osteoporosis [20]. Evidently, minimizing
the risk of acquiring the disease begins by modification
of individuals’ life style to combat related risk factors
and identification of patients at high risk to reduce fu-
ture fractures. Many risk factors, some are modifiable
and others non-modifiable are associated with osteopor-
osis. The major non-modifiable risk factors include ad-
vanced age, a personal history of fractures as an adult,
and a history of fracture in a first degree relative [21,22].
Major modifiable risk factors include a low BMD,
chronic oral corticosteroid use (more than 3 months of
use), history of recurrent falls, and a low body weight
(less than 58 kg) [21-24]. Minor risk factors for MOF in-
clude, but are not limited to, inadequate nutritional
supplementation of vitamin D and calcium, impairedeyesight despite correction, high alcohol and tobacco
consumption, and immobilization [7,25,26].
Results of our study showed a good agreement with
published studies regarding risk factors that are signifi-
cantly associated with risk of fractures. However our re-
sults showed no significant association between the risk
of fractures and BMI or regular exercise. In our study,
the 10-year probability of MOF was significantly associ-
ated with higher age, female gender and multi parity.
Our results are consistent with results published in lit-
erature where similar significant association between risk
of osteoporosis and such variables was found [15,21].
Previous fracture, presence of secondary osteoporosis,
rheumatoid arthritis, and administration of corticoster-
oid were also significantly associated with 10-year prob-
ability of HF and MOF. Similar results were found in
literature [21,23,24]. Smoking, exercising, and having a
history of cardiovascular diseases were not significantly
associated with 10-year probability of MOF. This may be
due to the small sample size which made it difficult to
obtain statistical difference. Gastrointestinal diseases and
diabetes mellitus were significantly associated with 10-
year probability of HF. This may be due to their contri-
bution to occurrence of secondary osteoporosis in this
region, increasing the rates of HF.
Our study has few limitations. First the sample was
limited to one district. It would be better if we could
have sample from the whole west bank, but high cost of
the DEXA was one of the barriers. Furthermore, the
sampling was carried out at specific times, dates and on
people attending a healthcare clinic. This might suggest
that most of those participants were not healthy adults
and this might affect the interpretation of our results
and might limit the generalization of our results to the
entire Palestinian population. In Palestine, recruitment
of participants for such study is a very difficult task
given the cultural barriers as well the nature of the test
which requires certain procedures that might not be ac-
ceptable for some people. Second, the majority of the
sample was females and obese people. Obesity is com-
mon among Palestinians particularly women [27]. This
might be due to decreased physical activity and greater
than necessary food consumption. In addition, leisure-
time physical activity is not a common concept in the
Palestinian context, especially for rural women, where
lack of sex-segregated facilities and cultural norms are
prohibitive factors. Women in urban areas face similar
cultural restrictions [27]. The prevalence of obesity among
participants might have increased the 10-year probability
estimation of bone fractures. Third, participants might
have made errors related to recalling certain events or
understanding certain questions. For example, most
participants were not able to report accurately the pres-
ence of rheumatoid arthritis. Participants reported a
Table 3 Association and correlation between 10-year
probability of MOF and HF with demographic and clinical
variables of the participants
Variable name Median (interquartile
range) 10-y prob. of
MOF; (P value)
Median (interquartile
range) 10-y prob. of
HF; (P value)
Age category
50 < Age ≤65 3.2% (2.20 – 6.08) 0.2% (0.00 – 0.48)
90 ≥ Age >65 4.9% (3.65 – 6.50) 0.5% (0.4 – 0.98)
P = 0.008a P < 0.001a
Gender
Male 3% (1.65 – 4.65) 0.2% (0.00 -0.45)
Female 3.8% (2.70 – 6.5) 0.4% (0.10 - 0.7)
P = 0.024a P = 0.087 a
Marital status
Married 3.5% (2.3 – 6.2) 0.3% (0.1 – 0.6)
Others 4.5% (3.2 – 5.55) 0.6% (0.25 – 0.95)
P = 0.47a P = 0.088a
Parity
Null parity 3.8% (2.58 - 4.4) 0.5% (0.15 – 0.6)
Have≤ 6 children 3% (2.30 – 5.3) 0.1% (0.08 – 0.4)
Have > 6 children 5.3% (2.95 – 7.5) 0.5% (0.25 – 1.0)
P = 0.003b P = 0.002b
Education level
Illiterate 5.4% (3.78 – 7.35) 0.55% (0.4 – 1.05)
School educated 3.4% (2.3 – 6.28) 0.3% (0.1 – 0.7)
Achieved university
degree
2.9% (2.15 – 3.98) 0.2% (0.1 – 0.4)
P = 0.01b P = 0.005b
Current tobacco use
Yes 3.4% (2.6 -5.6) 0.4% (0.2 – 0.7)
No 3.8% (2.3- 6.4) 0.3% (0.1 – 0.6)
P = 0.802a P = 0.199a
BMI - -
P = 0.576c, r = 0.057 P = 0.798c, r = −0.026
Exercise
Yes 3.1% (1.88 – 5.7) 0.2% (0.00 – 0.63)
No 3.8% (2.78 – 6.35) 0.4% (0.1 – 0.73)
P = 0.066a P = 0.098a
Previous fracture
Yes 6.75% (5.58 - 10.45) 0.7% (0.38 – 1.43)
No 3.2% (2.2 - 4.8) 0.2% (0.1 – 0.5)
P < 0.001a P < 0.001a
Previous parents’
hip fracture
Yes 7.2% (5.7 -13) 0.3% (0.3 – 1.1)
No 3.3% (2.3 – 5.3) 0.3% (0.1 – 0.65)
P < 0.001a P = 0.211a
Table 3 Association and correlation between 10-year
probability of MOF and HF with demographic and clinical
variables of the participants (Continued)
History of OCT use
Yes 3.4% (2.45 – 5.33) 0.3% (0.10 – 0.63)
No 3.9% (2.9 – 7.2) 0.4% (0.15 – 0.8)
P = 0.031a P = 0.115a
History of
corticosteroid use
Yes 6.7% (5.2 – 10.7) 0.55% (0.2 – 1.03)
No 3.05% (2.2 – 4.83) 0.3% (0.1 – 0.5)
P < 0.001a P = 0.031a
Secondary
osteoporosis
Yes 5.4% (3.9 – 7.2) 0.5% (0.3 – 1.2)
No 3.4% (2.3 – 5.65) 0.3% (0.1 – 0.6)
P = 0.013a P = 0.034a
Diabetes mellitus
Yes 4.9% (2.75 – 6.5) 0.4 (0.2 – 0.95)
No 3.4% (2.30 – 5.5) 0.3 (0.1 – 0.5)
P = 0.12a P = 0.024a
Cardiovascular
diseases
Yes 3.9% (2.5 – 6.18) 0.4% (0.1 – 0.7)
No 3.3% (2.3 – 6.05) 0.3% (0.1 – 0.6)
P = 0.418a P = 0.665a
Gastrointestinal tract
Disorders 4.9% (2.9 – 6.68) 0.5% (0.13 – 0.95)
Yes 3.35 (2.3 – 5.93) 0.25% (0.1 – 0.5)
No P = 0.09a P = 0.031a
Rheumatoid arthritis
Yes 5.3% (3.65 – 7.5) 0.6% (0.4 – 1.1)
No 3.3% (2.30 – 5.6) 0.2% (0.1 – 0.5)
P = 0.002a P = 0.003a
Abbreviations: SD standard difference, Q1-Q3 quartile 1, quartile 3, OCT oral
contraceptives, MOF major osteoporotic fracture, HF hip fracture, BMI body
mass index.
aStatistical significance of differences estimated with the Mann–Whitney U
test.
bStatistical significance of differences estimated with the Kruskal-Wallis test.
cStatistical significance of differences estimated with the Spearman's
correlation coefficient.
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ritis or osteoarithritis. However, we analyzed informa-
tion related to history or current joint pain as if it is
rheumatoid arthritis.
Conclusions
As a conclusion, our study indicated that osteoporosis is
common among the study sample where one fifth of the
participants had vertebral osteoporosis and 5% had hip
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was higher than that of HF and both were within
reported range of published results. There is an urgent
need of a comprehensive national program to screen for
osteoporosis in Palestine. More care and attention
should be targeted toward elderly and especially post-
menopausal female with respect to preventive measures.
More efforts on the level of MOH to adopt FRAX tool
to be used as a screening tool for all individuals above
40 years before making DEXA as an approximate esti-
mation of fracture risk is a priority. Increase awareness
toward osteoporosis and prevention strategies among
the general population and particularly in older popula-
tion. Further research and studies regarding fracture
rates, genetic component of osteoporosis, and evaluation
of the applicability accuracy and feasibility of FRAX in
Palestinian population are needed.
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